Nuvaring Insert, Extended Release
Product Images NDC 59212-146

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Nuvaring (NDC 59212-146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanz Pharma (us) Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Nuvaring 01)

A horizontal bar chart showing the number of women with a blood clot out of 10,000 woman-years (WY) for different groups: Non-CHC user non-pregnant, CHC user, pregnant, and postpartum (12 weeks only). Each group has a range representing the number of cases, with postpartum having the highest range and non-CHC non-pregnant the lowest.*

FDA Label Image

Figure 2 (Nuvaring 01a)

A forest plot chart showing effect estimates from multiple studies comparing contraceptive use outcomes. The x-axis represents effect estimates ranging from -1.50 to 2.00. Study names and authors with years are listed on the left side, with confidence intervals and point estimates marked by dots and horizontal lines on the right side. The chart visually compares odds ratios, relative risks, and hazard ratios for contraceptive use groups.*

FDA Label Image

Chemical Structure (Nuvaring 02)

Chemical structures of the active ingredients etonogestrel and ethinyl estradiol, showing their respective molecular formulas C22H28O2 and C20H24O2 as part of the NuvaRing contraceptive vaginal insert.*

FDA Label Image

Figure 3 (Nuvaring 03)

A line graph depicting plasma concentrations of etonogestrel and ethinyl estradiol (EE) over 21 days following NuvaRing vaginal insertion. The y-axis on the left shows etonogestrel levels in pg/mL, and the y-axis on the right shows EE levels in pg/mL. Etonogestrel levels rise sharply then plateau, while EE levels remain relatively stable and lower throughout the period.*

FDA Label Image

Figure 3 (Nuvaring 04)

An illustration showing effectiveness of various contraceptive methods categorized by pregnancies per 100 women per year. From most to least effective: implants, injections, intrauterine devices, sterilization; birth control pills, skin patch, vaginal ring with hormones; condoms, diaphragm; no sex during fertile days, spermicide, withdrawal; and no birth control at highest pregnancy rates.*

FDA Label Image

Figure 4 (Nuvaring 05)

A horizontal bar chart depicting the number of women with a blood clot per 10,000 woman-years across four categories: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women (within 12 weeks). The chart shows ranges for each group with postpartum women having the highest range between 40 to 65 cases, followed by pregnancy (5 to 20), CHC users (3 to 12), and non-CHC, non-pregnant users (1 to 5).*

FDA Label Image

Figure A, Figure B, Figure C (Nuvaring 06)

An instructional diagram with three figures showing different body positions for insertion of NuvaRing vaginal insert. Figure A illustrates a person lying down with knees bent, Figure B shows a person squatting, and Figure C depicts a person standing with one foot elevated on a step.*

FDA Label Image

Figure D, Figure E (Nuvaring 07)

Illustrations show hands demonstrating how to handle the NuvaRing insert. Figure D depicts a hand holding the circular ring at its edge, while Figure E shows a hand pinching the ring between fingers, likely representing insertion or removal technique for the vaginal contraceptive insert.*

FDA Label Image

Figure F (Nuvaring 08)

An anatomical illustration showing the placement of NuvaRing inside the vagina, relative to the uterus. Labels identify the uterus, vagina, and the NuvaRing contraceptive insert within the vaginal canal.*

FDA Label Image

Figure G (Nuvaring 09)

An anatomical illustration showing the proper placement of the NuvaRing vaginal insert within the female reproductive system. The image depicts the ring positioned inside the vaginal canal, relative to the uterus and surrounding anatomy.*

FDA Label Image

Figure H (Nuvaring 10)

An anatomical illustration showing the female pelvic region with the NuvaRing vaginal insert positioned inside the vaginal canal. The image highlights the placement of the extended release contraceptive insert within the body.*

FDA Label Image

Figure I (Nuvaring 11)

An instructional anatomical illustration showing a sagittal cross-section of female pelvic anatomy with the vaginal canal. The diagram demonstrates placement of a vaginal insert, represented by a ring positioned inside the vaginal canal. The image is related to NuvaRing, an extended-release vaginal insert containing etonogestrel and ethinyl estradiol.*

FDA Label Image

Figure J (Nuvaring 12)

An anatomical illustration showing the female reproductive system with a hand demonstrating the insertion of the NuvaRing vaginal contraceptive ring. The image highlights the proper placement inside the vaginal canal.*

FDA Label Image

Principle Display Panel (3 Ring Pouch Carton)

Packaging label for NuvaRing vaginal ring insert delivering 0.120 mg etonogestrel and 0.015 mg ethinyl estradiol per day. The label includes storage instructions to refrigerate between 2°C to 8°C before dispensing, contains 3 rings per package, and is marked Rx only. Manufactured for Advanz Pharma (US) Corp., with additional manufacturing by N.V. Organon in the Netherlands.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.